Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 77 clinical trials
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma (TACE)

Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of

TACE
liver cancer
hepatitis
prothrombin
hepatectomy
  • 2 views
  • 13 Feb, 2022
  • 1 location
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.

TACE
platelet count
neutrophil count
tubal ligation
  • 0 views
  • 26 Dec, 2021
  • 8 locations
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

The purpose of this study is to determine the safety and efficacy of immunotherapy durvalumab and tremelimumab combined with DEB-TACE in patients with Hepatocellular Carcinoma.

TACE
durvalumab
chemoembolization
measurable disease
ascites
  • 5 views
  • 17 Mar, 2022
  • 1 location
DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC

This study is conducted to evaluate the efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) compared with conventional transarterial chemoembolization (cTACE) as the

  • 0 views
  • 26 Jul, 2021
  • 1 location
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)

Background Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Most people with advanced HCC survive an average of 6 to 9 months. Researchers are evaluating a combination of treatment drugs to delay the progression of HCC; aiming to help people with HCC live longer. Objective To …

TACE
cancer
pet scan
measurable disease
neutrophil count
  • 0 views
  • 18 Sep, 2022
  • 1 location
TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label Single-arm Phase 2 Trial

, transarterial chemoembolization (TACE) is a preferential and standard treatment of unresectable HCC. TACE has been proved to provide outstanding efficacy for treating advanced stage HCC patients. However, TACE

TACE
hepatectomy
antineoplastic
cancer
hepatic arterial infusion
  • 0 views
  • 29 Sep, 2021
  • 1 location
SBRT or TACE for Advanced HCC

Randomized study of stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) in locally advanced hepatocellular carcinoma.

TACE
radiofrequency ablation
prothrombin
stereotactic body radiation therapy
ethanol injection
  • 18 views
  • 09 Dec, 2021
  • 1 location
TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma

The current standard treatment for intermediate-stage HCC (BCLC stage B) is transcatheter arterial chemoembolization (TACE) alone.The combination of TACE with RFA has also reported to be an

TACE
metastasis
chemoembolization
tumour thrombus
transcatheter arterial chemoembolisation
  • 2 views
  • 21 Jan, 2021
  • 1 location
  • 0 views
  • 15 Sep, 2022
  • 1 location
Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;

This is a multicenter, randomized, parallel controlled study to determine the efficacy and safety of transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma

  • 0 views
  • 15 Feb, 2021
  • 1 location